Active, not recruitingPhase 2NCT03698994
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Studying Ependymal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Kieuhoa T VoChildren's Oncology Group
- Intervention
- Pharmacokinetic Study(other)
- Enrollment
- 20 enrolled
- Eligibility
- 12-21 years · All sexes
- Timeline
- 2018 – 2022
Study locations (20)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Banner Children's at Desert, Mesa, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Mattel Children's Hospital UCLA, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03698994 on ClinicalTrials.govOther trials for Ependymal tumor
Additional recruiting or active studies for the same condition.